Obesity Increases Infectious Disease Risk
Analysis based on 39 articles · First reported Feb 09, 2026 · Last updated Feb 11, 2026
The study's findings highlight the significant public health burden of obesity, potentially increasing demand for weight management solutions, including pharmaceuticals like GLP-1 receptor agonist, and influencing public health policy decisions. This could lead to increased investment in healthcare sectors focused on obesity prevention and treatment.
A new study published in The Lancet, led by Solja Nyberg from the University of Helsinki and Mika Kivimäki from University College London, reveals that individuals with obesity face a 70% higher risk of hospitalization or death from infectious diseases, including influenza, pneumonia, gastroenteritis, urinary tract infections, and COVID-19. The research, which analyzed data from over 540,000 people in the United Kingdom and Finland, estimates that obesity contributed to 0.6 million (10.8%) of the 5.4 million infectious disease deaths globally in 2023. The study also found that the risk increases with the severity of obesity, with those having a BMI of 40 or higher facing three times the risk. While the link was not explained by other obesity-related chronic conditions or lifestyle factors, evidence from trials of GLP-1 receptor agonist suggests that weight loss can reduce the risk of severe infections. Co-author Sara Ahmadi-Abhari from Imperial College London cautioned about interpreting global impact estimates due to data accuracy in low-resource countries. The researchers emphasize the urgent need for public health policies promoting healthy weight management, including access to affordable nutritious foods and opportunities for physical activity, and stress the importance of vaccination for individuals with obesity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard